BREAST CARCINOMA ANTIGENS F36/22 AND M7/105

将使用单抗进行免疫学和生化研究 识别表达决定簇的抗体F36/22和M7/105 对乳腺癌的影响最大。其体内分布和分子水平 这些抗原的特征将通过对大型 正常组织和肿瘤组织的面板。抗体F36/22和M7/105将 用于免疫组织化学染色研究，以便 表型--对原发和转移性乳腺癌进行分类。这个 这些抗体的免疫治疗适用性将在 体外抗乳腺癌细胞株和体内应用人乳腺癌细胞 荷瘤裸鼠。乳腺癌抗原将通过以下方式提纯 生化分馏程序的使用应包括 单抗-配基层析。将使用纯化的抗原 为血清学分析生成免疫分析程序，以便 获取有关这些测试在诊断和诊断中的价值的基线数据 患者管理应用程序。

Immunological and biochemical studies will be performed using monoclonal antibodies F36/22 and M7/105 which recognize determinants expressed maximally on breast carcinomas. The in vivo distribution and molecular profile of these antigens will be determined by analysis against a large panel of normal and tumor tissues. Antibodies F36/22 and M7/105 will be employed in immunohistochemical staining studies in order to phenotypically-classify primary and metastatic breast carcinomas. The immunotherapeutic applicability of these antibodies will be examined in vitro against breast carcinoma cell lines and also in vivo using human tumor-bearing athymic mice. Breast carcinoma antigens will be purified by the use of biochemical fractionation procedures which shall include monoclonal antibody-ligand chromatography. Purified antigen will be used to generate immunoassay procedures for serologic analyses in order to obtain baseline data regarding the value of these tests in diagnostic and patient management applications.